brentuximab vedotin
takeda,seagen
[]
echelon - 1 trial updated results out at asco 2022. overall survival advantage with the use a-avd compared to abvd. what is the debate now? #asco2022 american society of clinical oncology (asco) 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"